Evaluation of Rapid vs Standard Infliximab Infusions in the Pediatric Population.

Evaluation of Rapid vs Standard Infliximab Infusions in the Pediatric Population. Inflamm Bowel Dis. 2018 May 18;: Authors: Rozette NA, Hellauer CM, McKee C, Vazifedan T, Gabriel CA, Dice JE, Yokois NU Abstract Background: Rapid 1-hour infliximab infusions have been safely implemented in adults, but studies of these rapid infusions in pediatric patients are limited. This study’s primary objective was to determine the safety of 1-hour infliximab infusions compared with standard 2- to 3-hour infusions in children with inflammatory bowel disease and other autoimmune disorders. Methods: We conducted an institutional…

Read More

Impact of Obesity on Short- and Intermediate-Term Outcomes in Inflammatory Bowel Diseases: Pooled Analysis of Placebo Arms of Infliximab Clinical Trials.

Impact of Obesity on Short- and Intermediate-Term Outcomes in Inflammatory Bowel Diseases: Pooled Analysis of Placebo Arms of Infliximab Clinical Trials. Inflamm Bowel Dis. 2018 May 18;: Authors: Singh S, Proudfoot J, Xu R, Sandborn WJ Abstract Background and aims: To assess whether obesity may affect natural history of inflammatory bowel diseases (IBD), we conducted an individual participant data (IPD) pooled analysis of placebo arms, using data from clinical trials of infliximab in IBD and using the Yale Open Data Access (YODA) Project. Methods: We obtained IPD from 4 placebo-controlled…

Read More

Modeling Immunization To Infliximab in Children With Crohn’s Disease Using Population Pharmacokinetics: A Pilot Study.

Modeling Immunization To Infliximab in Children With Crohn’s Disease Using Population Pharmacokinetics: A Pilot Study. Inflamm Bowel Dis. 2018 May 18;: Authors: Petitcollin A, Leuret O, Tron C, Lemaitre F, Verdier MC, Paintaud G, Bouguen G, Willot S, Bellissant E, Ternant D Abstract Background: Antidrug antibodies (ADAs) dramatically increase infliximab clearance and are responsible for underexposure to the drug, leading to treatment failure. This pilot study aimed at developing a population pharmacokinetic model to detect and describe an early increase in infliximab clearance due to ADA. Methods: Twenty children with…

Read More

The Impact of Combination Therapy on Infliximab Levels and Antibodies in Children and Young Adults With Inflammatory Bowel Disease.

Related Articles The Impact of Combination Therapy on Infliximab Levels and Antibodies in Children and Young Adults With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Apr 26;: Authors: Chi LY, Zitomersky NL, Liu E, Tollefson S, Bender-Stern J, Naik S, Snapper S, Bousvaros A Abstract Goal: The aim of this study was to evaluate the effect of combination therapy with methotrexate or 6-mercaptopurine on infliximab levels (IFXL) and antibodies to infliximab (ATI). Background: Infliximab (IFX) is a highly effective therapy for inflammatory bowel disease (IBD). Unfortunately, 25%-50% of patients will…

Read More

Asymptomatic hyperCKemia During Infliximab Therapy in Patients With Inflammatory Bowel Disease.

Related Articles Asymptomatic hyperCKemia During Infliximab Therapy in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Apr 30;: Authors: Theodoraki E, Orfanoudaki E, Foteinogiannopoulou K, Koutroubakis IE Abstract Background: Both muscle-related complaints and elevated serum creatine kinase (CK) levels have been reported in patients with inflammatory bowel disease (IBD) treated with infliximab (IFX), mainly as case reports. The aim of this study was to investigate the effect of IFX therapy on serum CK levels in a cohort of Greek IBD patients. Methods: Demographic, clinical (including muscle complaints), and laboratory…

Read More

Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn’s Disease.

Related Articles Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn’s Disease. Inflamm Bowel Dis. 2018 Apr 28;: Authors: Papamichael K, Rakowsky S, Rivera C, Cheifetz AS, Osterman MT Abstract Background and aim: Objective and more rigorous therapeutic outcomes are emerging as novel targets in Crohn’s disease (CD). We investigated the association between maintenance serum infliximab trough concentrations and biochemical, endoscopic, or histologic remission in CD. Methods: This retrospective multicenter study involved consecutive CD patients treated with infliximab who had a serum…

Read More

Higher Infliximab Levels Are Not Associated With an Increase in Adverse Events in Inflammatory Bowel Disease.

Related Articles Higher Infliximab Levels Are Not Associated With an Increase in Adverse Events in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Apr 25;: Authors: Greener T, Kabakchiev B, Hillary Steinhart A, Silverberg MS Abstract Background: Patients requiring optimization of therapy for suboptimal response and/or targeting more robust outcomes may eventually reach high serum levels. Data evaluating the relationship between infliximab concentration and toxicity are limited. The aim of this study was to evaluate the frequency of adverse events (AEs) in inflammatory bowel disease (IBD) patients with infliximab higher-range (HR)…

Read More

Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn’s Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials.

Related Articles Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn’s Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials. J Crohns Colitis. 2018 Apr 25;: Authors: Panaccione R, Sandborn WJ, D’Haens G, Wolf DC, Berg S, Maa JF, Petersson J, Robinson AM Abstract Background and Aims: In the 4-week GAIN clinical trial, adalimumab was efficacious in inducing remission in patients with moderate to severe Crohn’s disease (CD) who had prior loss of response/intolerance to infliximab. The efficacy and safety of adalimumab in…

Read More

Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis.

Related Articles Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis. J Crohns Colitis. 2018 Apr 06;: Authors: Kevans D, Murthy S, Mould DR, Silverberg MS Abstract Background and Aims: A significant proportion of patients with corticosteroid-refractory acute ulcerative colitis [UC] fail therapy. We aimed to assess the pharmacokinetics [PK] of infliximab [IFX] in patients with corticosteroid-refractory acute UC and determine the association between induction IFX PK and short- and long-term therapy outcome. Methods: A population PK model was developed using data from…

Read More
<< Go Back